Global Neurocutaneous Disorder Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI08253446

Publication Date:

August 19, 2024

Pages:

108

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord. These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late.
The global Neurocutaneous Disorder market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淣eurocutaneous Disorder Industry Forecast鈥� looks at past sales and reviews total world Neurocutaneous Disorder sales in 2023, providing a comprehensive analysis by region and market sector of projected Neurocutaneous Disorder sales for 2024 through 2030. With Neurocutaneous Disorder sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurocutaneous Disorder industry.
This Insight Report provides a comprehensive analysis of the global Neurocutaneous Disorder landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurocutaneous Disorder portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Neurocutaneous Disorder market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurocutaneous Disorder and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurocutaneous Disorder.
The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurocutaneous Disorder market by product type, application, key players and key regions and countries.
Segmentation by type
Tuberous Sclerosis (TS)
Neurofibromatosis (NF)
Sturge-Weber Syndrome
Von Hippel-Lindau (VHL)
Ataxia-Telangiectasia (A-T)
Others
Segmentation by application
Hospitals
Clinics
Diagnostic Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Johnson & Johnson
Medtronic
Abbott
Novartis
Roche
Sanofi
Takeda
Allergan
Syneron Medical
Aleva NeurOthersapeutics
Abbott Laboratories
Bausch Health

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurocutaneous Disorder Market Size 2019-2030
2.1.2 Neurocutaneous Disorder Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neurocutaneous Disorder Segment by Type
2.2.1 Tuberous Sclerosis (TS)
2.2.2 Neurofibromatosis (NF)
2.2.3 Sturge-Weber Syndrome
2.2.4 Von Hippel-Lindau (VHL)
2.2.5 Ataxia-Telangiectasia (A-T)
2.2.6 Others
2.3 Neurocutaneous Disorder Market Size by Type
2.3.1 Neurocutaneous Disorder Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neurocutaneous Disorder Market Size Market Share by Type (2019-2024)
2.4 Neurocutaneous Disorder Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Diagnostic Centers
2.4.4 Others
2.5 Neurocutaneous Disorder Market Size by Application
2.5.1 Neurocutaneous Disorder Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neurocutaneous Disorder Market Size Market Share by Application (2019-2024)
3 Neurocutaneous Disorder Market Size by Player
3.1 Neurocutaneous Disorder Market Size Market Share by Players
3.1.1 Global Neurocutaneous Disorder Revenue by Players (2019-2024)
3.1.2 Global Neurocutaneous Disorder Revenue Market Share by Players (2019-2024)
3.2 Global Neurocutaneous Disorder Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Neurocutaneous Disorder by Regions
4.1 Neurocutaneous Disorder Market Size by Regions (2019-2024)
4.2 Americas Neurocutaneous Disorder Market Size Growth (2019-2024)
4.3 APAC Neurocutaneous Disorder Market Size Growth (2019-2024)
4.4 Europe Neurocutaneous Disorder Market Size Growth (2019-2024)
4.5 Middle East & Africa Neurocutaneous Disorder Market Size Growth (2019-2024)
5 Americas
5.1 Americas Neurocutaneous Disorder Market Size by Country (2019-2024)
5.2 Americas Neurocutaneous Disorder Market Size by Type (2019-2024)
5.3 Americas Neurocutaneous Disorder Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurocutaneous Disorder Market Size by Region (2019-2024)
6.2 APAC Neurocutaneous Disorder Market Size by Type (2019-2024)
6.3 APAC Neurocutaneous Disorder Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neurocutaneous Disorder by Country (2019-2024)
7.2 Europe Neurocutaneous Disorder Market Size by Type (2019-2024)
7.3 Europe Neurocutaneous Disorder Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurocutaneous Disorder by Region (2019-2024)
8.2 Middle East & Africa Neurocutaneous Disorder Market Size by Type (2019-2024)
8.3 Middle East & Africa Neurocutaneous Disorder Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Neurocutaneous Disorder Market Forecast
10.1 Global Neurocutaneous Disorder Forecast by Regions (2025-2030)
10.1.1 Global Neurocutaneous Disorder Forecast by Regions (2025-2030)
10.1.2 Americas Neurocutaneous Disorder Forecast
10.1.3 APAC Neurocutaneous Disorder Forecast
10.1.4 Europe Neurocutaneous Disorder Forecast
10.1.5 Middle East & Africa Neurocutaneous Disorder Forecast
10.2 Americas Neurocutaneous Disorder Forecast by Country (2025-2030)
10.2.1 United States Neurocutaneous Disorder Market Forecast
10.2.2 Canada Neurocutaneous Disorder Market Forecast
10.2.3 Mexico Neurocutaneous Disorder Market Forecast
10.2.4 Brazil Neurocutaneous Disorder Market Forecast
10.3 APAC Neurocutaneous Disorder Forecast by Region (2025-2030)
10.3.1 China Neurocutaneous Disorder Market Forecast
10.3.2 Japan Neurocutaneous Disorder Market Forecast
10.3.3 Korea Neurocutaneous Disorder Market Forecast
10.3.4 Southeast Asia Neurocutaneous Disorder Market Forecast
10.3.5 India Neurocutaneous Disorder Market Forecast
10.3.6 Australia Neurocutaneous Disorder Market Forecast
10.4 Europe Neurocutaneous Disorder Forecast by Country (2025-2030)
10.4.1 Germany Neurocutaneous Disorder Market Forecast
10.4.2 France Neurocutaneous Disorder Market Forecast
10.4.3 UK Neurocutaneous Disorder Market Forecast
10.4.4 Italy Neurocutaneous Disorder Market Forecast
10.4.5 Russia Neurocutaneous Disorder Market Forecast
10.5 Middle East & Africa Neurocutaneous Disorder Forecast by Region (2025-2030)
10.5.1 Egypt Neurocutaneous Disorder Market Forecast
10.5.2 South Africa Neurocutaneous Disorder Market Forecast
10.5.3 Israel Neurocutaneous Disorder Market Forecast
10.5.4 Turkey Neurocutaneous Disorder Market Forecast
10.5.5 GCC Countries Neurocutaneous Disorder Market Forecast
10.6 Global Neurocutaneous Disorder Forecast by Type (2025-2030)
10.7 Global Neurocutaneous Disorder Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Neurocutaneous Disorder Product Offered
11.1.3 Pfizer Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Neurocutaneous Disorder Product Offered
11.2.3 Johnson & Johnson Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Medtronic
11.3.1 Medtronic Company Information
11.3.2 Medtronic Neurocutaneous Disorder Product Offered
11.3.3 Medtronic Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Medtronic Main Business Overview
11.3.5 Medtronic Latest Developments
11.4 Abbott
11.4.1 Abbott Company Information
11.4.2 Abbott Neurocutaneous Disorder Product Offered
11.4.3 Abbott Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Abbott Main Business Overview
11.4.5 Abbott Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Neurocutaneous Disorder Product Offered
11.5.3 Novartis Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Roche
11.6.1 Roche Company Information
11.6.2 Roche Neurocutaneous Disorder Product Offered
11.6.3 Roche Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Roche Main Business Overview
11.6.5 Roche Latest Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Neurocutaneous Disorder Product Offered
11.7.3 Sanofi Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Sanofi Main Business Overview
11.7.5 Sanofi Latest Developments
11.8 Takeda
11.8.1 Takeda Company Information
11.8.2 Takeda Neurocutaneous Disorder Product Offered
11.8.3 Takeda Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Takeda Main Business Overview
11.8.5 Takeda Latest Developments
11.9 Allergan
11.9.1 Allergan Company Information
11.9.2 Allergan Neurocutaneous Disorder Product Offered
11.9.3 Allergan Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Allergan Main Business Overview
11.9.5 Allergan Latest Developments
11.10 Syneron Medical
11.10.1 Syneron Medical Company Information
11.10.2 Syneron Medical Neurocutaneous Disorder Product Offered
11.10.3 Syneron Medical Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Syneron Medical Main Business Overview
11.10.5 Syneron Medical Latest Developments
11.11 Aleva NeurOthersapeutics
11.11.1 Aleva NeurOthersapeutics Company Information
11.11.2 Aleva NeurOthersapeutics Neurocutaneous Disorder Product Offered
11.11.3 Aleva NeurOthersapeutics Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Aleva NeurOthersapeutics Main Business Overview
11.11.5 Aleva NeurOthersapeutics Latest Developments
11.12 Abbott Laboratories
11.12.1 Abbott Laboratories Company Information
11.12.2 Abbott Laboratories Neurocutaneous Disorder Product Offered
11.12.3 Abbott Laboratories Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Abbott Laboratories Main Business Overview
11.12.5 Abbott Laboratories Latest Developments
11.13 Bausch Health
11.13.1 Bausch Health Company Information
11.13.2 Bausch Health Neurocutaneous Disorder Product Offered
11.13.3 Bausch Health Neurocutaneous Disorder Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Bausch Health Main Business Overview
11.13.5 Bausch Health Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂